

Statement of Education and Qualifications

Name

Academic Qualification(s)

Alejandro Martínez Muñoz	MD
--------------------------	----

Address

CENTRO DERMATOLOGICO SCHEJTMAN/ Av. Paunero 1994, (C1663) Buenos Aires, Argentina

Telephone Number

FAX Number

00 54 11-30015777	
-------------------	--

Education and Training

Name and Location of Institution	Degree and Year Awarded	Area of Study
Universidad de Buenos Aires. Buenos Aires. Argentina	MD. 2007	Medicine Medical License: 122.470
Hospital Córdoba. Córdoba. Universidad Nacional de Córdoba	2011	Internal Medicine
Hospital Municipal de Agudos "Dr. E. Tornú" Buenos Aires City. Argentina. Universidad de Buenos Aires	2015	Rheumatology

Professional Experience

Position/Title	Name and Location of Institution	Dates
Current Principal Investigator Rheumatologist /Rheumatology	Centro_Dermatologico Schejtmán, San Miguel (B1663), Buenos Aires	Since Mar2021 – to present
Current Rheumatologist	Hospital Zonal General de Agudos "Dr. C.A. Bocalandro" Loma Hermosa – Tres de Febrero (1657)	Since Oct2022 – to present
Current Rheumatologist	"San Miguel Arcángel Hospital". Bella Vista, Buenos Aires	Since mar2016 to Present
Previous Principal Investigator	Fundación Respirar, CABA, Argentina	Since oct2018 to mar2021
Previous Sub Investigator	Centro de Investigación Reumatologica, Buenos, Aires, Argentina	Sep2011 to Feb2016

Other documents evidencing experience or expertise attached: YES ☒ NO ☐ If yes, specify below

Sub-Investigator / Principal Investigator in the trials listed below:

- Protocol A3921024 – Anti-JAK, **Rheumatoid Arthritis**; Phase II, PFIZER S.R.L ARGENTINA (2012-2015)
- Protocol CNT0148ART3001 VERSION 10/9/09 – **Rheumatoid Arthritis**; Phase III, PAREXEL INTERNACIONAL S.A. (2010-2011)
- Protocol PSA001, **Psoriatic Arthritis**, Phase III, UCB CELLTECH, (2010- 2011)
- Protocol GP13-2013 – **Rheumatoid Arthritis**, Phase II, NOVARTIS ARGENTINA S.A. (2011-2012)
- Protocol 107-00, **Rheumatoid Arthritis**, Phase III, MERCK SHARP Y DOHME (ARGENTINA) (2011-2012)
- Protocoo PSA001 – **Psoriatic Arthritis**, Phase III, UCB CELLTECH (2010-2012)
- Protocol HGS1006-C1115- **Systemic Lupus Erythematosus**, Phase III, HUMAN GENOME SCIENCES INC (2012-2014)
- Protocol 1301.1 – **Rheumatoid Arthritis**, Phase III, BOEHRINGER INGELHEIM (2013 – 2014)
- Protocol VERSION 27 JUL 2012 – **Rheumatoid Arthritis** Phase III, ELI LILLY, (2013 – 2015)
- Protocol CNT0148PSA3001, **Psoriatic Arthritis**, Phase III, JANSSEN (2016-2017)
- Protocol NCT03980483, **Rheumatoid Arthritis**, Phase III; GSK/IQVIA, contrast 1 (2019-2022)
- Protocol NCT04134728, **Rheumatoid Arthritis**, Phase III; GSK/IQVIA contrast 3, (2018-2022)
- Protocol NCT04333147, III (2019), **Rheumatoid Arthritis**, Phase III, GSK/IQVIA contrast x, (2021-2022)
- Protocol NCT04058028, **Systemic Lupus Erythematosus**, Phase II, AMG570- on-going. (2021-on-going)

15. Protocol NCT04961567, **Systemic Lupus Erythematosus**, Phase III, Biogen/IQVIA (Topaz-2) (2022-on-going)
16. Protocol NCT04647708, **Systemic Lupus Erythematosus**, Phase II, Merck/IQVIA (Willow Study) (2022)
17. Protocol NCT05540327, **Systemic Lupus Erythematosus**, Phase II LTE, Merck/IQVIA (Willow LTE) (2022)
18. Protocol NCT05523167, **Active Idiopathic Inflammatory Myopathy**, Phase II/III, ARGX/ICON (ALKIVIA)(2022)
19. Protocol NCT04930094, **Giant Cell Arteritis**, Phase III, Novartis, (2022)

Date last GCP training undertaken: 08dec2021: - 08dec2024 GCP Course, NIDA Clinical Trials

Signature **Martínez Muñoz Alejandro, MD**

Date **12-Nov-2022**